I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $406M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Apovia AG |
Martinsried, Germany |
4/22 |
EUR19 |
Apovia raised US$17.1M in a third-round funding led by Heidelberg Innovation; other investors were Genavent, Societe Generale Asset Management, VCH Equity Group AG, 3i, Global Life Science Holding II GmbH, Oxford Bioscience Partners and private individuals; Arthur Andersen Corporate Finance acted as adviser |
Axovan AG |
Basel, Switzerland |
4/22 |
CHF30 |
Axovan raised US$18.2M in its second-round financing through a private placement led by Atlas Venture; other investors were Heidelberg Innovation, NeoMed Banque Cantonale Vaudoise Private Equity, and all existing investors |
BioStratum Inc. |
Research Triangle Park, N.C. |
4/29 |
$20 |
BioStratum raised $20M with investors HealthCap, MP Bio hf, Equity Resources Group Inc. and BankInvest |
BioSyntech Inc. |
Laval, Quebec |
4/3 |
C$2.5 |
BioSyntech received a US$1.6M debt financing from BDC Venture Capital |
CancerVax Corp. |
Carlsbad, Calif. |
4/4 |
$55 |
CancerVax raised $55M in its second round; investors included JP Morgan Fleming Asset Management, Schroder Ventures Life Sciences, CDIB BioScience Ventures, Windamere Venture Partners LLC, GE Capital's Capital Funding business, Endpoint Late Stage Fund LP, Athenian Venture Partners, Forward Ventures, Vector Fund Management LP, Amerindo Investment Advisors Inc., China Development Industrial Bank, GMG Capital Partners and a group of institutional and private investors |
CareX |
Paris |
4/17** |
EUR6 |
CareX raised US$5.2M in an initial funding round; the lead investor was Sofinnova Partners; other investors were GIMV and Mara Ventures |
Celeres Pharmaceuticals Inc. |
Tustin, Calif. |
4/3 |
$0.5 |
Celeres raised $500,000 in its Series A round |
Cell Based Delivery Inc. |
Providence, R.I. |
4/2 |
$9 |
Cell Based Delivery raised $9M in a financing round led by TVM Techno Venture Management and including ABN AMRO and The Vertical Group |
Dynavax Technologies Inc. |
Berkeley, Calif. |
4/25 |
$34.8 |
Dynavax raised $34.8M in a private placement led by Care Capital LLC; other investors were Piper Jaffray Ventures, Bioveda, HealthCap, Lotus Bioscience Holdings, Forward Ventures, Sanderling, BA Ventures, WestLB Asset Management, JAFCO, Alta Partners, InterWest, Axiom Venture Partners and Finedix |
EGeen International Corp. |
Redwood City, Calif. |
4/3 |
$2 |
EGeen completed a $2M private financing led by the SEAF CEE Growth Fund and The Baltics Small Equity Fund |
Faust Pharmaceuticals |
Paris |
4/24** |
EUR3 |
Faust closed an initial funding round raising US$2.6M; Sofinnova Partners was the lead investor; Auriga Partners also participated |
Gyros AB |
Uppsala, Sweden |
4/11 |
$36 |
Gryos raised $36M in a financing involving several investors including Schroder Ventures Life Sciences |
Hybrigenics SA |
Paris |
4/12 |
EUR16.8 |
Hybrigenics raised US$14.8M in a Series C round of capital funding; the placement was led by Life Sciences Partners, and included new investors Banexi Venture Partners and funds managed by La Compagnie Financiere Edmond de Rothschild; existing investors were IMH, Lombard Odier and Alafi Capital |
Inhibitex Inc. |
Atlanta |
4/18 |
$3.6 |
Inhibitex raised $3.6M in a Series D round, bringing the total raised to $45M; the company raised $41.4M in February; investors in the most recent financing were Burrill & Co. and William Blair Capital Partners |
Kalypsys Inc. |
San Diego |
4/2 |
$43 |
Kalypsys raised $43M in its first round led by the Sprout Group, and co-led by Tavistock Life Sciences; other investors included CMEA Ventures, Lombard Odier & Cie, Novartis BioVenture Fund, Aravis Ventures, and the individual investor Alejandro Zaffaroni |
Medlyte Inc. |
San Diego |
4/15 |
$3.5 |
Medlyte raised $3.5M in a Series A round; investors were Johnson & Johnson Development Corp. and Western States Investment Group |
Microbia Inc. |
Cambridge, Mass. |
4/2 |
$26 |
Microbia raised $26M in a Series C financing led by Fidelity Biosciences Group; other investors were Venrock Associates, Polaris Venture Partners, Essex Investment Management Co., Aberdare Ventures and BancBoston Ventures, as well as numerous other private investors |
Newron Pharmaceuticals SpA |
Gerenzano, Italy |
5/1** |
EUR18.5 |
Newron raised US$16.7M in a financing led by Atlas Venture |
OxoN Medica Inc. |
San Francisco |
4/29 |
$3.9 |
OxoN raised $3.9M as part of its Series A financing round |
Plexxikon Inc. |
Berkeley, Calif. |
4/16 |
$27 |
Plexxikon completed a Series B financing, raising $27M; investors were Walden International, GIMV, A.M. Pappas, Alta Partners, CW Group, Advanced Technology Ventures and Kumho Group |
Regenesis Biomedical Inc. |
Scottsdale, Ariz. |
4/22 |
$2.8 |
Regenesis completed a Series A round of nearly $2.8M; the funds were invested by Solstice Capital LP, Tucson Ventures LLC, Village Ventures Inc. and Aztec Venture Network LLC |
Replicon Technologies Inc. |
Danville, Calif. |
4/3 |
$0.4 |
Replicon received $3M in financing from Johnson & Johnson Development Corp.; in addition to money raised in January from Tullis Dickerson & Co. Inc., the company has raised a total of $5.4M in its first round, $5M of which was accounted for in the January chart |
Replidyne Inc. |
Louisville, Colo. |
4/25 |
$13 |
Replidyne raised $13M in a Series A financing led by HealthCare Ventures; other investors were Sequel Venture Partners, Morganthaler Ventures and Johnson & Johnson Research and Development LLC |
Signase Inc. |
Houston |
4/30 |
$3.5 |
Signase raised $3.5M in a Series A financing; investors were A.M. Pappas & Associates and Tripos Inc. |
Syntonix Pharmaceuticals Inc. |
Waltham, Mass. |
4/16 |
$35.8 |
Syntonix raised $35.8M in a Series B financing led by Bay City Capital LLC and Alta Partners; other investors were A.M. Pappas & Associates, Global Biomedical Partners, The AFB Fund, Venrock Associates, BancBoston Ventures, Merrill Lynch Ventures, and others |
TargeGen Inc. |
San Diego |
4/3 |
$10 |
TargeGen raised $10M in a Series A financing led by Forward Ventures; Enterprise Partners and other investors also participated |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS | ||||
FROM EXISTING CORPORATE PARTNERS: $6.1M | ||||
Company* (Symbol)# |
Partner (Country) |
Amt. (M) |
Triggering Event |
Details (Date) |
Exelixis Inc. (EXEL) |
Bayer AG (Germany) |
ND |
Milestone |
Exelixis earned a milestone payment for identifying and validating pesticide targets (4/15) |
Innate Pharma SAS* (France) |
Inserm Transfert (France) |
ND |
Equity investment |
Inserm took an equity investment in Innate; the investment is a mix of stock and options (4/29) |
MorphoSys AG (Germany; Neuer Markt:MOR) |
ImmunoGen Inc. (IMGN) |
ND |
Milestone payment |
MorphoSys received a payment for delivering several antibodies against a cancer target molecule to ImmunoGen (4/3) |
Nastech Pharmaceutical Co. Inc. (NSTK) |
Pharmacia Corp. |
$2 |
Milestone payment |
Nastech received a $2M payment as part of its agreement with Pharmacia for the development and commercialization of intranasal apomorphine (4/3) |
Pharmacopeia Inc. (PCOP) |
Mitsubishi Pharma Corp. (Japan) |
ND |
Milestone payment |
Pharmacopeia received a milestone payment as part of its collaboration with Mitsubishi Pharma to identify compounds against a Mitsubishi target (4/2) |
Structural GenomiX Inc.* |
Cystic Fibrosis Foundation Therapeutics Inc. |
ND |
Milestone payment |
Structural received a milestone payment for its progress in solving the 3-dimensional structure of a complex protein called cystic fibrosis transmembrane conductance regulator (4/11) |
SurroMed Inc.* |
PPD Inc. (PPDI) |
ND |
Equity investment |
SurroMed received the investment from PPD (4/18) |
The Immune Response Corp. (IMNR) |
NovaRx Corp.* |
$0.1 |
Milestone payment |
The Immune Response Corp. received the milestone payment when NovaRx enrolled the first patient in a Phase II trial of an experimental cancer vaccine in people with lung cancer (4/24) |
Unigene Laboratories Inc. (UGNE) |
GlaxoSmithKline plc (UK) |
$3 |
Signing and milestone payment |
Unigene received the payment as part of a $150M collaboration to develop an oral parathyroid hormone product for the prevention and treatment of osteoporosis (4/29) |
Vical Inc. (VICL) |
Merial (joint venture of Merck & Co. Inc. and Aventis SA; France) |
$1 |
Payment |
The payment is for the exercise of options under a 1995 agreement for veterinary preventive infectious disease vaccines (4/15) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed | ||||
To read more on related topics, click on one of the words below.